Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Fletcher and Frank Hodi.
Connection Strength

0.692
  1. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
    View in: PubMed
    Score: 0.160
  2. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.143
  3. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-?B pathways. . 2012 Sep; 11(9):1905-14.
    View in: PubMed
    Score: 0.133
  4. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One. 2012; 7(1):e29622.
    View in: PubMed
    Score: 0.129
  5. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 01; 14(23):7726-32.
    View in: PubMed
    Score: 0.104
  6. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.